Allan T. van Oosterom

Author

KU Leuven

Also Known As

Allan T Van Oosterom, Allan T van Oosterom, Allan T. Oosterom, Allan T. Van Oosterom, Allan T. van Oosterom

Publications

27.3K

Citations

H-Index

102

Concepts

All Affiliations

KU Leuven Universitair Ziekenhuis Leuven European Organisation for Research and Treatment of Cancer Antwerp University Hospital University of Antwerp

About

Allan T. van Oosterom is an author at KU Leuven specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	42	23.3K
2	Health Sciences	8	8	16.5K
3	Natural Sciences	2	2	35
4	Engineering	1	1	15
5	Public Health	1	1	19

Allan T. van Oosterom

Publications

24.7K

Citations

H-Index

Page 1

	Year	Citations
New Guidelines to Evaluate the Response to Treatment in Solid Tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, JNCI Journal of the National Cancer Institute World Health OrganizationSolid TumorsCancer ManagementMetronomic ChemotherapyResponse Assessment	2000	15.7K
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial George D. Demetri, Allan T. van Oosterom, Christopher R. Garrett, The Lancet Gastrointestinal OncologyMedicinePathologyColorectal CancerCancer Treatment	2006	2.6K
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study Allan T. van Oosterom, Ian Judson, Jaap Verweij, The Lancet OncologyGastrointestinal OncologyMedicinePathologyCancer Treatment	2001	1.3K
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours Maria Dêbiec‐Rychter, Raf Sciot, Axel Le Cesne, European Journal of Cancer OncologyGastrointestinal OncologyMedicineKit MutationsDose Selection	2006	893
New guidelines to evaluate the response to treatment in solid tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, Breast Cancer Solid TumorsMedicineCancer ManagementNew GuidelinesCancer Treatment	2005	662
Soft tissue sarcomas of adults: state of the translational science. Ernest C. Borden, Laurence H. Baker, Robert S. Bell, PubMed Single Gene FamilyImatinib MesylateGastrointestinal OncologyMedicineTranslational Science	2003	616
Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical Trials Piotr Rutkowski, M. van Glabbeke, Cathryn Rankin, Journal of Clinical Oncology	2010	398
Clinical and Molecular Studies of the Effect of Imatinib on Advanced Aggressive Fibromatosis (desmoid tumor) Michael C. Heinrich, Grant A. McArthur, George D. Demetri, Journal of Clinical Oncology	2006	315
Initial and Late Resistance to Imatinib in Advanced Gastrointestinal Stromal Tumors Are Predicted by Different Prognostic Factors: A European Organisation for Research and Treatment of Cancer–Italian Sarcoma Group–Australasian Gastrointestinal Trials Group Study M. van Glabbeke, Jaap Verweij, Paolo G. Casali, Journal of Clinical Oncology Imatinib DoseEuropean OrganisationDifferent Prognostic FactorsGastrointestinal OncologyMalignant Disease	2005	279
Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group Allan T. van Oosterom, Ian Judson, Jaap Verweij, European Journal of Cancer Tumoral PathologyBone Sarcoma GroupGastrointestinal OncologyMalignant DiseaseMedicine	2002	234

Page 1